These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 27294527)

  • 1. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
    J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
    Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.
    Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A
    Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
    Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
    J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
    Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
    PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
    Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
    J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.
    Blazar BR; Carreno BM; Panoskaltsis-Mortari A; Carter L; Iwai Y; Yagita H; Nishimura H; Taylor PA
    J Immunol; 2003 Aug; 171(3):1272-7. PubMed ID: 12874215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.
    Saha A; Taylor PA; Lees CJ; Panoskaltsis-Mortari A; Osborn MJ; Feser CJ; Thangavelu G; Melchinger W; Refaeli Y; Hill GR; Munn DH; Murphy WJ; Serody JS; Maillard I; Kreymborg K; van den Brink M; Dong C; Huang S; Zang X; Allison JP; Zeiser R; Blazar BR
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
    Juchem KW; Sacirbegovic F; Zhang C; Sharpe AH; Russell K; McNiff JM; Demetris AJ; Shlomchik MJ; Shlomchik WD
    J Immunol; 2018 Jan; 200(2):834-846. PubMed ID: 29212909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
    Cassady K; Martin PJ; Zeng D
    Front Immunol; 2018; 9():3061. PubMed ID: 30622541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.
    Al-Chaqmaqchi H; Sadeghi B; Abedi-Valugerdi M; Al-Hashmi S; Fares M; Kuiper R; Lundahl J; Hassan M; Moshfegh A
    PLoS One; 2013; 8(4):e60367. PubMed ID: 23593203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
    Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
    J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
    Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
    J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1's Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant.
    Handelsman S; Overbey J; Chen K; Lee J; Haj D; Li Y
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of T-cell-suppressive PD-L1
    Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
    Okiyama N; Katz SI
    J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.